Entera Bio Ltd.

ENTX

NASDAQHealthcareBiotechnology

Open in GoAI

Latest quote

$3.24

+$0.01 · +0.31%

Aug 21, 3:55 PM ET

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

32/100

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

Overpriced

Momentum

Neutral

Sentiment

Bullish

Risk resilience

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Entera Bio Ltd. is a biopharmaceutical firm in the clinical development phase, dedicated to creating and marketing oral medications composed of large molecules, addressing medical conditions that currently lack adequate treatments. Its primary experimental drugs are EB612, currently undergoing Phase II clinical assessment for hypoparathyroidism, and EB613, which has concluded Phase II studies for osteoporosis and is now in Phase I trials for treating non-healing bone fractures. Furthermore, the company holds a collaborative research and licensing pact with Amgen Inc. aimed at identifying and advancing potential therapeutic compounds for inflammatory conditions and other grave ailments. Established in 2009, Entera Bio Ltd. operates from its headquarters in Jerusalem, Israel.

Industry: Biotechnology
Sector: Healthcare
Headquarters: IL
CEO: Miranda J. Toledano
Listed since: Jun 28, 2018
Employees: 21